ALLMedicine™ Facioscapulohumeral Dystrophy Center

May 1st, 2021 - Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). This study included Part A: 10 healthy volunteers (HVs) randomized to single oral doses of ...

Jan 14th, 2021 - To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. All FSHD tests performed in the diagnostic laboratory from January 2015 to July 2019 were retrospecti...

Jan 13th, 2021 - Facioscapulohumeral dystrophy (FSHD) is an inherited muscular dystrophy clinically characterised by muscle weakness starting with the facial and upper extremity muscles. A disease model has been developed that postulates that failure in somatic re...

Nov 20th, 2020 - This study examines the correlation, and clinical meaningfulness, between reachable workspace outcome and reported activities of daily living (ADL) function of individuals with facioscapulohumeral dystrophy (FSHD). Twenty-one FSHD subjects with va...

Oct 19th, 2020 - Facioscapulohumeral dystrophy (FSHD) is characterized by a loss of repressive epigenetic marks leading to the aberrant expression of the DUX4 transcription factor. In muscle, DUX4 acts as a poison protein though the induction of multiple downstrea...

May 1st, 2021 - Evaluate safety, tolerability, pharmacokinetics (PK), and target engagement (TE) of losmapimod in blood and muscle in facioscapulohumeral dystrophy (FSHD). This study included Part A: 10 healthy volunteers (HVs) randomized to single oral doses of ...

Jan 14th, 2021 - To summarize facioscapulohumeral muscular dystrophy (FSHD) diagnostic testing results from the University of Iowa Molecular Pathology Laboratory. All FSHD tests performed in the diagnostic laboratory from January 2015 to July 2019 were retrospecti...

Jan 13th, 2021 - Facioscapulohumeral dystrophy (FSHD) is an inherited muscular dystrophy clinically characterised by muscle weakness starting with the facial and upper extremity muscles. A disease model has been developed that postulates that failure in somatic re...

Nov 20th, 2020 - This study examines the correlation, and clinical meaningfulness, between reachable workspace outcome and reported activities of daily living (ADL) function of individuals with facioscapulohumeral dystrophy (FSHD). Twenty-one FSHD subjects with va...

Oct 19th, 2020 - Facioscapulohumeral dystrophy (FSHD) is characterized by a loss of repressive epigenetic marks leading to the aberrant expression of the DUX4 transcription factor. In muscle, DUX4 acts as a poison protein though the induction of multiple downstrea...